The latest news on the launch and price of Erdafitinib tablets in 2025: focusing on the innovative direction of FGFR target therapy

In January 2025, China's National Medical Products Administration (NMPA) officially approved Erdafitinib (Erdafitinib, trade name: Boco) for the treatment of patients with metastatic urothelial cancer carrying FGFR3 gene mutations. This decision marks a key step in the treatment of bladder cancer in China, and also brings revolutionary changes to the diagnosis and treatment model of the fourth most common cancer in the world. This article will combine the latest clinical data and real-world research to provide an in-depth analysis of the clinical value and application strategy of erdafitinib.

xa0

1. What kind of medicine is erdafitinib? Analysis of mechanism of action

Erdafitinib (Erdafitinib, trade name Balversa) is an oral small molecule targeted drug developed by Johnson & Johnson (Janssen) for the treatment of patients with advanced or metastatic urothelial cancer harboring FGFR gene mutations. It is the world's first approved inhibitor targeting the FGFR (fibroblast growth factor receptor) pathway. This target has been proven to be closely related to abnormal cell growth, drug resistance and tumor recurrence in a variety of tumors.

The drug blocks the signaling pathway by inhibiting the kinase activity of FGFR1–4, reducing cancer cell proliferation and promoting apoptosis. Unlike traditional chemotherapy, erdafitinib directly targets the molecular abnormalities of tumors and is a typical representative of "precision therapy". Its innovative significance lies in allowing patients with urothelial cancer to receive personalized treatment plans based on genetic characteristics rather than the location of the disease.

xa0

2. Indications and latest clinical directions

As of 2025, erdafitinib has been approved in the United States for the treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 mutations, especially after failure of platinum-based chemotherapy. At the end of 2024, the FDA will also include it in the accelerated review channel for clinical research in combination with immunotherapy drugs.

In the latest international multi-center study, researchers explored the potential of erdafitinib combined withPD-1/PD-L1 inhibitors. This combination of "immunity + targeting" is expected to break through the bottleneck of single drug efficacy and improve long-term remission rates. In addition, research on FGFR mutant solid tumors such as cholangiocarcinoma, endometrial cancer, and glioblastoma is also ongoing, showing broader application prospects.

xa0

xa0

3.The latest research trends in 2025: The trend of precision medicine is obvious

According to2025 updates from the New England Journal of Medicine (NEJM) and ClinicalTrials.gov, erdafitinib showed interesting long-term follow-up data in the latest phase III trial. The study noted that a subset of patients maintained stable disease after more than two years of treatment, which is rare in the history of urothelial cancer treatment.

At the same time, researchers have discovered that genetic testing has become the "ticket" for erdafitinib treatment. Determining the type of FGFR mutation through liquid biopsy or tissue sequencing is key to determining whether a patient is suitable for the drug. International guidelines also recommend that FGFR2/3 mutations should be routinely detected in all patients with advanced urothelial cancer to achieve more precise targeted treatment strategies.

xa0

4. Dosage methods and medication precautions

Stepped dosing schedule: The initial dose is8 mg/day, and serum phosphorus levels are assessed on days 14-21:

If serum phosphorus<5.5 mg/dL and there are no grade ≥2 adverse reactions, increase the dose to 9 mg/day

If serum phosphate≥9.0 mg/dL, initiate phosphate binder therapy

PersistentGrade 4 hyperphosphatemia without relief for 4 weeks requires permanent discontinuation of the drug

Data support:BLC2001 study showed that the ORR of patients in the 9mg dose group reached 42%, which was 10 percentage points higher than that in the 8mg group, but the incidence of grade 3 adverse reactions increased by 15%.

xa0

Because this drug affects phosphorus metabolism in the body, patients need to follow their doctor's diet and have regular blood tests. In actual use, common adverse reactions include hyperphosphatemia, oral ulcers, rash, nail changes, fatigue and eye discomfort. Some patients may develop blurred vision or retinal pigment epithelial detachment (RPED), so ophthalmological monitoring is important. If vision loss occurs, the medication should be stopped promptly and contact a doctor.

xa0

5. Overseas market prices and medical insurance progress

In mainland China,In December 2023, erdafitinib was included in the CDE priority review channel; it was officially approved in January 2025, becoming the first FGFR inhibitor in China. As of October 2025, erdafitinib has not yet been fully included in the national medical insurance catalog, and the current price is unclear, which puts many patients under great financial pressure.

In comparison, the price of foreign original drug erdafitinib is relatively high, especially in developed countries such as the United States, where the average monthly treatment cost is about several thousand dollars. The prices of generic drugs in some countries, such as the Laos version and the Bangladeshi version, are relatively low, usually ranging from a few hundred yuan to more than 2,000 yuan, making them an alternative choice for some patients.

xa0

xa0

6. Future Direction: From Single Target to Combined Precision Therapy

The success of erdafitinib has verified the strategic position of the FGFR pathway in tumor treatment. Future research will focus more on the following three major directions:

(1) combined with immunotherapy to improve the response rate by improving the tumor microenvironment;

(2) combined with anti-angiogenic drugs to improve the control of complex mutated tumors;

(3) Develop a new generation of reversible FGFR inhibitors to reduce toxicity and prolong efficacy.

Janssen's latest strategic document released in 2025 shows that the company is deploying erdafitinib's "next-generation combination therapy," including global research plans for FGFR-mutated cholangiocarcinoma and a variety of rare tumors, indicating that its application scope will continue to expand.

xa0

xa0

7. Balance between patient perspective and clinical reality

Although erdafitinib has significantly improved the quality of life of some patients, clinical experts also point out that its efficacy is highly dependent on the type of FGFR mutation, and drug resistance still requires continued attention. Once secondary mutations occur, tumors may reactivate the FGFR pathway or switch to other signaling networks. Therefore, dynamic genetic monitoring and individualized adjustment plans have become core strategies for future treatment.

For patients, before choosing erdafitinib, they should conduct systematic genetic testing and evaluation, and use the drug rationally under the guidance of a doctor. The indications for erdafitinib are strictly limited to patients with locally advanced/metastatic urothelial carcinoma who carry FGFR3 or FGFR2 gene mutations. Long-term users should pay attention to eye examinations and electrolyte monitoring to maximize efficacy and reduce risks. In clinical practice, the genetic mutation status must be confirmed through next-generation sequencing (NGS) technology, and this drug is prohibited for those who have not been tested.

xa0

8. Conclusion:The era of FGFR targets is coming

Erdafitinib in 2025 is no longer just a "targeted drug for urothelial cancer", but a symbol of the era of precision medicine. It further implements the concept of "gene-determined therapy" and provides a new paradigm for personalized treatment of tumors. In the future, with the rise of combination therapy, early application and artificial intelligence-assisted diagnosis and treatment, the FGFR pathway is expected to become a new strategic high ground in tumor treatment.

xa0

References:

U.S. Food and Drug Administration (FDA): www.fda.gov

National Cancer Institute (Cancer.gov): www.cancer.gov

Janssen Oncology official site: www.janssen.com

ClinicalTrials.gov – Erdafitinib studies

The New England Journal of Medicine (NEJM) 2025 Updates

xa0